Baird Financial Group’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-3,000
Closed -$269K – 2011
2026
Q2
$269K Hold
3,000
– – ﹤0.01% 1767
2026
Q1
$238K Hold
3,000
– – ﹤0.01% 1718
2025
Q4
$246K Hold
3,000
– – ﹤0.01% 1696
2025
Q3
$210K Sell
3,000
-865
-22% -$58.5K ﹤0.01% 1723
2025
Q2
$248K Buy
3,865
+1
+0% +$62 ﹤0.01% 1649
2025
Q1
$245K Hold
3,864
– – ﹤0.01% 1632
2024
Q4
$257K Hold
3,864
– – ﹤0.01% 1606
2024
Q3
$270K Hold
3,864
– – ﹤0.01% 1571
2024
Q2
$250K Buy
3,864
+280
+8% +$17.7K ﹤0.01% 1612
2024
Q1
$232K Buy
3,584
+309
+9% +$20.1K ﹤0.01% 1631
2023
Q4
$216K Buy
+3,275
New +$190K ﹤0.01% 1622
2022
Q1
– Sell
-3,000
Closed -$214K – 1902
2021
Q4
$214K Hold
3,000
– – ﹤0.01% 1799
2021
Q3
$225K Hold
3,000
– – ﹤0.01% 1768
2021
Q2
$232K Sell
3,000
-12
-0.4% -$892 ﹤0.01% 1648
2021
Q1
$222K Hold
3,012
– – ﹤0.01% 1613
2020
Q4
$211K Buy
+3,012
New +$191K ﹤0.01% 1496
2020
Q3
– Sell
-3,613
Closed -$211K – 1551
2020
Q2
$211K Buy
+3,613
New +$197K ﹤0.01% 1405
2020
Q1
– Sell
-3,613
Closed -$202K – 1521
2019
Q4
$202K Buy
+3,613
New +$188K ﹤0.01% 1459
2015
Q3
– Sell
-5,158
Closed -$301K – 1301
2015
Q2
$301K Buy
+5,158
New +$295K ﹤0.01% 1121

Other funds holding PBE

Baird Financial Group's PBE Position: Q3 2026 in Review

Baird Financial Group sold out of Invesco Biotechnology & Genome ETF (PBE) in Q3 2026, closing a stake of 3,000 shares — an estimated $269K sold.

Baird Financial Group first reported a position in PBE in Q2 2015 and held it in 19 quarters. The position peaked at $301K in Q2 2015. 123 funds tracked by Wall St. Rank hold PBE as of Q3 2026.

  • Baird Financial Group reported no remaining Invesco Biotechnology & Genome ETF position as of Q3 2026 after selling out during the quarter.
  • Baird Financial Group sold 3,000 Invesco Biotechnology & Genome ETF shares in Q3 2026, an estimated $269K.
  • Baird Financial Group first reported a position in Invesco Biotechnology & Genome ETF in Q2 2015 and held it in 19 quarters.
  • Baird Financial Group's Invesco Biotechnology & Genome ETF position peaked at $301K in Q2 2015.
  • 123 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q3 2026.

Based on Baird Financial Group's 13F filing for Q3 2026, filed 13 Nov 2026.